About Telomir Pharmaceuticals Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://telomirpharma.com/
Frequently Asked Questions
What is the 52-week range for TELO?
The 52-week high is $2.091 and the 52-week low is $0.8884.
What is the P/E ratio for TELO?
The P/E ratio data is currently unavailable.
What is the dividend yield for TELO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -102.69%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 7.73.
Latest TELO News
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-market session. The market value of their outstanding shares is at $14.8 million. Geovax Labs (NASDAQ:GOVX) stock rose
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock increased by
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its Metal-Dependent Epigenetic BiologyMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, rest
Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4
Maxim Group analyst Jason McCarthy initiates coverage on Telomir Pharmaceuticals (NASDAQ:TELO) with a Buy rating and announces Price Target of $4.
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
Preclinical Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site InitiationMIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell g
Telomir Announces New Research Findings From Ohio State University College Of Veterinary Medicine Showing Telomir-Zn Produces Inhibition Of Cell Growth Across Human And Canine Osteosarcoma Models
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-21 | Aminov Erez | -2,000,000 | - | - |
| 2026-05-21 | Aminov Erez | +2,000,000 | - | - |
| 2026-05-21 | Aminov Erez | -1,960,170 | - | - |
| 2026-05-21 | Aminov Erez | +1,960,170 | - | - |
| 2026-05-21 | Whalen Matthew Pratt | -25,000 | - | - |
| 2026-05-21 | Whalen Matthew Pratt | +25,000 | - | - |
| 2026-05-21 | MacPherson Edward Clouston | -25,000 | - | - |
| 2026-05-21 | MacPherson Edward Clouston | +25,000 | - | - |
| 2026-05-21 | Del Giudice Matthew Paul | -25,000 | - | - |
| 2026-05-21 | Del Giudice Matthew Paul | +25,000 | - | - |
| 2026-04-22 | Aminov Erez | +7,319,710 | $1.37 | $10,028,003 |
| 2026-04-16 | Whalen Matthew Pratt | +50,000 | - | - |
| 2026-04-16 | Del Giudice Matthew Paul | +50,000 | - | - |
| 2026-04-16 | MacPherson Edward Clouston | +50,000 | - | - |